Stockscreener 앱 받기
3.98
0.25%
0.010
시간 외 거래:
3.98
Protara Therapeutics Inc 주식(TARA)의 최신 뉴스
Assenagon Asset Management S.A. Sells 507,667 Shares of Protara Therapeutics, Inc. $TARA - MarketBeat
Protara Therapeutics (NASDAQ:TARA) Downgraded to Strong Sell Rating by Wall Street Zen - MarketBeat
HC Wainwright Issues Negative Forecast for TARA Earnings - MarketBeat
Protara Therapeutics, Inc. Actuals & Estimates (NASDAQ:TARA) - TradingView
Dimensional Fund Advisors LP Grows Stock Holdings in Protara Therapeutics, Inc. $TARA - MarketBeat
Janus Henderson Group (TARA holder) reports 8.4% Protara Therapeutics stake via Managed Portfolios - Stock Titan
H.C. Wainwright Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $27 - Moomoo
JonesTrading Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Protara Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Protara Therapeutics Inc Lymphatic Malformations KOL Webinar Transcript - GuruFocus
Form 8K Protara Therapeutics Inc For: 11 August By Investing.com - Investing.com South Africa
Protara Therapeutics (NASDAQ:TARA) Issues Earnings Results - MarketBeat
Protara Therapeutics (TARA) Advances Clinical Trials Amid Mixed Market Signals - GuruFocus
Protara Therapeutics, Inc. 2Q 2026: Net income $(21.7)M, EPS $(0.36) — 10-Q Summary - TradingView
Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update - The Manila Times
Protara Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Protara Therapeutics reports Q2 2026 net loss $21.7M, cash ~$162M to fund operations into 2028 - TradingView
Protara Therapeutics: Q2 Earnings Snapshot - AOL.com
Protara Posts $21.7 Million Q2 Loss as Pipeline Milestones Near - Quiver Quantitative
Protara Therapeutics rated Buy with $9.96 fair value, advancing treatments for NMIBC and choline deficiency. - Pluang
Protara Therapeutics: Orphan Drug Indications Drive A Heavily Undervalued Pipeline - Seeking Alpha
Protara Therapeutics (TARA) Rises Modestly to $4.12 as Stock Consolidates Between Key LevelsDark Pool Sentiment - dars.gov.et
Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Protara Therapeutics Inc (TARA) Balance Sheet - TradingKey
Protara Therapeutics Inc (TARA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TARA|Protara Therapeutics Inc|Price:3.975|Chg%:+0.055 - TradingKey
Protara Therapeutics Inc (TARA) Institutional Confidence - TradingKey
TARA|Protara Therapeutics Inc|Price:3.938|Chg%:-0.102 - TradingKey
TARA|Protara Therapeutics Inc|Price:4.030|Chg%:+0.010 - TradingKey
TradingKey - TradingKey
Does TARA Stock’s 15% After-Hours Slump Signal A Bargain After New Bladder Cancer Data? - Stocktwits
Walleye Capital LLC Boosts Position in Protara Therapeutics, Inc. $TARA - MarketBeat
What Makes Protara Therapeutics (TARA) a New Buy Stock - Yahoo Finance
Should I buy Protara Therapeutics (TARA) - Zacks Investment Research
Protara Therapeutics (TARA) Edges Higher, Approaches Key Resistance Amid Low VolumePCR Extreme - dars.gov.et
Protara Therapeutics Q1 2026 Earnings: Narrower Loss Amid Continued Clinical DevelopmentHigh Growth Earnings - dars.gov.et
What's Driving Protara's Recent Surge - Kavout | AI
Protara Therapeutics (TARA) Edges Higher by 2.86%, Testing Resistance Near $4.54Growth Stock Picks - dars.gov.et
Millennium Group and Israel Englander report 5.7% stake in Protara (TARA) - Stock Titan
Protara Therapeutics focuses on rare disease programs as development continues - Ad Hoc News
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer - GlobeNewswire
Enterprise value to EBITDA forward of Protara Therapeutics, Inc. – NASDAQ:TARA - TradingView
Protara Therapeutics, Inc. Actuals & Estimates (HAM:1KPA) - TradingView
uniQure, Protara, Abeona, Cerebras, Verisign Insider Shake-Up - TipRanks
Protara Therapeutics (TARA) Holds Steady Near Support, Faces Resistance at $4.26Shakeout Pattern - dars.gov.et
Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Illumina (ILMN) and Protara Therapeutics (TARA) - The Globe and Mail
Protara Therapeutics (TARA) CEO exercises options, sells 215,687 shares and makes 30,000-share gifts - Stock Titan
Enterprise value to EBITDA forward of Protara Therapeutics, Inc. – GETTEX:1KPA - TradingView
Protara Therapeutics, Inc. Files Form 8-K with NASDAQ Listing and Company Details (2026) - Minichart
Form 144 PROTARA THERAPEUTICS For: 29 June By Investing.com - Investing.com South Africa
Protara Therapeutics Announces Key Medical Leadership Transition - TipRanks
Protara Therapeutics (TARA) CMO Leonardo Nicacio resigns, duties reassigned - Stock Titan
[144] Protara Therapeutics, Inc. SEC Filing - Stock Titan
TARAProtara Therapeutics Inc Options - Finviz
Protara Therapeutics, Inc. Actuals & Estimates (MUN:1KPA) - TradingView
Protara Therapeutics, Inc. Actuals & Estimates (SWB:1KPA) - TradingView
Enterprise value to revenue forward of Protara Therapeutics, Inc. – NASDAQ:TARA - TradingView
Protara Therapeutics, Inc. Actuals & Estimates (FWB:1KPA) - TradingView
Enterprise value to revenue forward of Protara Therapeutics, Inc. – FWB:1KPA - TradingView
TARA Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of Protara Therapeutics, Inc. – NASDAQ:TARA - TradingView
1.80%
1.77%
자본화:
|
볼륨(24시간):